Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,473.47
(
0.37%
)
US TECH 100
28,985.60
(
0.99%
)
Dow Jones
50,579.70
(
0.58%
)
Brent Oil
95.61
(
-5.50%
)
Bitcoin
77,245.10
(
-0.03%
)
News Focus
News Focus
Post# of 257628
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

ThomasS

Send PM Follow Ignore
Followers 12
Posts 2277
Boards Moderated 0
Alias Born 05/05/2005

ThomasS

Re: None

Thursday, 10/21/2010 6:03:15 PM

Thursday, October 21, 2010 6:03:15 PM

Post# of 257628
MNTA: I'll say it for the umpteenth time: NVS has every reason to buy MNTA rather than splitting revenues on Lovenox and, possibly, Copaxone. MNTA's market cap represents but an asterisk on the NVS balance sheet. (After consuming Alcon)

"If we don't succeed, we run the risk of failure."
-Dan Quayle

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today